Acute Esophageal Reactions from Proton Beam Therapy and Concurrent Chemotherapy for Non-Small Cell Lung Cancer: Reduction in Incidence and Severity Despite Higher Doses

Reviewer: James M. Metz, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 22 de mayo del 2007

Share article


Presenter: R. Komaki
Presenter's Affiliation: MD Anderson Cancer Center
Type of Session: Scientific

Background
In the United States, concurrent chemotherapy and radiation therapy is standard for unresectable NSCLC.  However, there is significantly increased toxicity with concurrent radiochemotherapy as opposed to sequential treatment.  There has also been evidence that esophageal toxicity can be reduced when 2D versus 3D treatment planning is utilized, but still remains very high.  Protons, due to the better dose distribution, may further reduce toxicity particularly in the era of concurrent chemotherapy and radiation therapy.  This study reports on the acute toxicity in the initial patients treated with combined chemotherapy and proton therapy for NSCLC.

Materials and Methods

  • Initial 25 patients treated at the MD Anderson Proton Therapy Center for NSCLC with combined chemotherapy and proton therapy.
  • Acute toxicity in the first 90 days after the initiation of treatment is reported.
  • Patients received carboplatin and taxol based chemotherapy in two separate clinical trials
  • Comparisons where made to matched patients who received 3D conformal radiation therapy from the same treatment team
  • Proton dose was 74 CGE while the 3D Conformal radiation dose was 63 Gy

 

Results

  • Esophageal reactions for any grade were 60% (Proton) vs 93% (3D)
  • Esophageal reactions by grade included 16% vs 27% for grade I, 28% vs 45% for Grade 2, 16% vs 20% for GrAD 3, and 0% vs 1% for grade 4, for protons vs 3D Conformal respectively
  • Patients received their chemotherapy dosing in in 100% of the proton therapy treatments and 93% of the 3D conformal treatments

Author's Conclusions

  • This is the first report of proton beam therapy and concurrent chemotherapy
  • The data suggest that higher total doses are achievable with proton beam therapy and concurrent chemotherapy without and increase in incidence or severity of esophageal reactions

Clinical/Scientific Implications

Although preliminary, this study makes an important contribution to the understanding of the combination of chemotherapy and proton therapy. Although a formal statistical comparison was not performed, acute toxicity of combined modality treatment was not increased by giving proton therapy to substantially higher doses then 3D conformal treatment.  This is an important concept with moving forward with proton therapy.  Proton therapy by itself will most likely not show significant improvements in survival.  It is the combination of protons with chemotherapy and targeted biologic agents have the promise to make substantial impacts in overall survival and improve cancer care.  We are currently very limited in our ability to combine a number of radiosensitizing chemotherapy agents due to the tolerance of normal tissues to radiation therapy.  Proton therapy may completely change this paradigm.


News
Significant improvement in progression free survival for non-small-cell lung cancer patients

Jul 7, 2011 - Erlotinib is superior to chemotherapy for improving progression free survival in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations, with acceptable toxicity, according to a study presented at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer and held from July 3 to 7 in Amsterdam, Netherlands.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información